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Breakthrough attacks in patients 
with hereditary angioedema receiving 
long-term prophylaxis are responsive 
to icatibant: findings from the Icatibant 
Outcome Survey
Werner Aberer1*, Marcus Maurer2, Laurence Bouillet3, Andrea Zanichelli4, Teresa Caballero5, Hilary J. Longhurst6, 
Amandine Perrin7, Irmgard Andresen7 and for the IOS Study Group
Abstract 
Background: Patients with hereditary angioedema (HAE) due to C1-inhibitor deficiency (C1-INH-HAE) experience 
recurrent attacks of cutaneous or submucosal edema that may be frequent and severe; prophylactic treatments 
can be prescribed to prevent attacks. However, despite the use of long-term prophylaxis (LTP), breakthrough attacks 
are known to occur. We used data from the Icatibant Outcome Survey (IOS) to evaluate the characteristics of break-
through attacks and the effectiveness of icatibant as a treatment option.
Methods: Data on LTP use, attacks, and treatments were recorded. Attack characteristics, treatment characteristics, 
and outcomes (time to treatment, time to resolution, and duration of attack) were compared for attacks that occurred 
with versus without LTP.
Results: Data on 3228 icatibant-treated attacks from 448 patients with C1-INH-HAE were analyzed; 30.1% of attacks 
occurred while patients were using LTP. Attack rate, attack severity, and the distribution of attack sites were similar 
across all types of LTP used, and were comparable to the results found in patients who did not receive LTP. Attacks 
were successfully treated with icatibant; 82.5% of all breakthrough attacks were treated with a single icatibant injec-
tion without C1-INH rescue medication. Treatment outcomes were comparable for breakthrough attacks across all LTP 
types, and for attacks without LTP.
Conclusions: Patients who use LTP should be aware that breakthrough attacks can occur, and such attacks can be 
severe. Thus, patients with C1-INH-HAE using LTP should have emergency treatment readily available. Data from IOS 
show that icatibant is effective for the treatment of breakthrough attacks. 
Trial Registration NCT01034969
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Background
Hereditary angioedema (HAE) is a rare genetic disor-
der characterized by recurrent attacks of cutaneous 
or submucosal edema associated with C1-inhibitor 
(C1-INH) deficiency (C1-INH-HAE type 1) or dysfunc-
tion (C1-INH-HAE type 2), leading to the overproduc-
tion of bradykinin, activation of bradykinin B2 receptors, 
capillary leakage, and local edema [1, 2].
It is recommended that all patients with C1-INH-HAE 
have access to therapy that can be used to treat acute 
angioedema attacks (“on-demand treatment”) [3–6]. In 
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addition, patients with C1-INH-HAE may receive long-
term prophylaxis (LTP) to reduce the frequency and 
severity of attacks [5]. However, despite the use of LTP, 
angioedema attacks, some of them severe, have been 
reported [7–11]. Therefore, patients receiving LTP also 
should carry an effective on-demand treatment for acute 
attacks. The characteristics of attacks occurring during 
LTP, referred to here as breakthrough attacks, have not 
been formally examined in depth. Furthermore, there 
are currently no reports evaluating treatments for break-
through attacks in detail.
Icatibant  (Firazyr®, Shire, Zug, Switzerland) is a subcu-
taneously administered bradykinin B2 receptor antago-
nist for the treatment of acute angioedema attacks in 
adults with type 1 or 2 C1-INH-HAE. The Icatibant 
Outcome Survey (IOS; NCT01034969) is an ongoing, 
prospective, international, observational study monitor-
ing the safety and effectiveness of icatibant during long-
term treatment in the real-world setting. We conducted 
an analysis of data from IOS to evaluate the character-
istics of breakthrough attacks, and compared them with 
attacks that did not occur during LTP. Outcomes follow-
ing treatment of these attacks with icatibant also were 
examined.
Methods
Study design and patients
Details for the design and conduct of IOS are described 
elsewhere [12]. IOS captures real-world data on treat-
ment with icatibant. Enrollment in IOS is open to all 
patients who have taken at least one dose of icatibant, 
regardless of attack frequency and level of icatibant usage. 
Patients with diagnosed C1-INH-HAE were included in 
this analysis [1]. Data on icatibant-treated attacks and 
LTP use were collected between July 2009 and February 
2016 via physician-completed electronic forms at rou-
tine visits (recommended at 6-month intervals), and with 
the aid of patient diaries. Characteristics of attacks and 
details regarding treatment with icatibant and any con-
comitant medications were recorded. Data on attacks 
and treatments during the 12 months before enrollment 
are referred to as historical. Attack severity was classified 
as very mild (very mild interference with daily activities), 
mild (mild interference with daily activities), moderate 
(moderate interference with daily activities and no other 
countermeasures required), severe (severe interference 
with daily activities with or without other countermeas-
ures), or very severe (very severe interference with daily 
activities and other countermeasures required).
The type of LTP administered, as well as dose, start 
and end dates, and frequency of dosing were recorded. 
Adherence to prophylaxis treatment was not moni-
tored. Attacks that occurred outside a start–end 
interval were considered to have occurred without 
LTP; attacks that occurred on the day that LTP started 
or ended were considered to have occurred with LTP. 
The total duration of treatment was calculated as the 
sum of the maximum duration of each type of LTP 
administered for each patient, irrespective of the 
occurrence of icatibant-treated attacks. The attack fre-
quency for each type of LTP was calculated by dividing 
the number of attacks by the total duration of treat-
ment. It was noted that some LTP regimens, such as 
androgens, had been started years before the avail-
ability of icatibant as a treatment option. To avoid 
underestimating the attack frequency, the date of LTP 
initiation was replaced with the date of the first treated 
attack if LTP began before the first treated attack. LTP 
regimens that started and stopped before the first 
treated attack were excluded.
Patients received subcutaneous injections of icatibant 
30 mg for acute attacks. Icatibant was self-administered 
(after training by a health care professional), or admin-
istered by a health care professional. Many patients self-
administered icatibant before the formal approval of this 
mode of administration in 2011.
Statistical analyses
Data comparisons were made for attacks occurring with 
LTP versus without LTP. Attacks with complete data for 
all three outcomes, (1) time to treatment (defined as time 
from attack onset to first icatibant injection), (2) time 
to resolution (defined as time from first icatibant injec-
tion to complete symptom resolution of all angioedema), 
and (3) duration of attack (defined as time from attack 
onset to complete resolution of symptoms), were com-
pared using a mixed-model analysis of repeated meas-
ures (PROC MIXED; SAS Institute Inc., Cary, NC). A 
generalized linear mixed-model for repeated measures 
(PROC GLIMMIX) was used to compare the severity of 
attacks (e.g., very mild/mild/moderate versus severe/very 
severe).
Results
Patient characteristics
Data from 3228 icatibant-treated attacks were analyzed 
from 448 patients with C1-INH-HAE. Most (94.4%) 
patients had a diagnosis of C1-INH-HAE type 1 and 
58.7% of patients were female. Demographic characteris-
tics of the patients are summarized in Table 1.
HAE attacks that occurred with and without LTP shared 
similar characteristics
Of the 3228 total icatibant-treated attacks recorded, 973 
(30.1%) attacks occurred in 171 patients during LTP 
(38.2% of the total 448 patients in this analysis), and 
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2255 (69.9%) attacks occurred in 323 patients (72.1%) 
who either never received LTP (n  =  277) or who were 
not using LTP at the time of the attack (n = 46; Table 2). 
The analysis included attacks that occurred over a mean 
(SD) duration of 3.5 (1.8) years per patient on LTP, and 
3.6 (1.8) years for patients who were not prescribed LTP 
(Table 3).
Androgens (danazol, oxandrolone, or stanozolol) 
were the most commonly used form of LTP. Androgens 
were used by 108/171 (63.2%) patients, while 43 (25.1%) 
patients used tranexamic acid and 15 (8.8%) patients used 
C1-INH. In addition, 17 (9.9%) patients used various 
combinations of these three medications. The mean (SD) 
duration of use was 3.5 (1.9), 3.4 (1.8), and 3.4 (1.4) years 
for androgens, tranexamic acid, and C1-INH, respec-
tively. The rate of icatibant-treated breakthrough attacks 
was similar irrespective of the type of prophylaxis; there 
were 1.5, 1.6, and 2.3 attacks/year reported in patients 
using androgens, tranexamic acid, and C1-INH for LTP, 
respectively. In comparison, there were 2.0 attacks/year 
in patients who never received LTP.
There were no statistically significant differences in 
attack severity in patients who used androgens, C1-INH, 
or tranexamic acid for LTP compared with attacks that 
occurred without LTP (Fig.  1a). In patients who used 
androgens for LTP, 68.9% of attacks were severe/very 
severe and 31.1% of attacks were very mild/mild/moder-
ate compared with 53.2 and 46.8%, respectively, in attacks 
without LTP (P = 0.056). The proportions of severe/very 
severe and very mild/mild/moderate attacks were compa-
rable between patients receiving C1-INH or tranexamic 
acid and were similar to those without LTP (P =  0.321 
and P = 0.989 for C1-INH and tranexamic acid, respec-
tively, versus patients without LTP).
The most frequent site of attack was the abdomen 
(47.6% with and 52.1% without LTP), followed by the 
skin (35.1 and 30.1%, respectively), and larynx (3.0 and 
5.0%, respectively; Fig.  1b). Multiple sites were affected 
in 12.0% of attacks with LTP and 10.5% of attacks with-
out LTP. The distribution of attack sites was comparable 
across the different types of LTP. Of the attacks involving 
the larynx or abdomen, 63.6 and 73.9%, respectively, were 
severe/very severe.
Table 1 Demographic characteristics
HAE hereditary angioedema, max maximum, min minimum
Characteristic Total
Patients, N 448
HAE diagnosis, n (%)
 Type 1 423 (94.4)
 Type 2 25 (5.6)
Sex, n (%)
 Female 263 (58.7)
 Male 185 (41.3)
Age at enrollment, y
 Mean (SD) 40.8 (14.7)
 Median (min, max) 39.1 (16.5, 81.8)
Country, n (%)
 France 119 (26.6)
 Spain 69 (15.4)
 Germany 57 (12.7)
 United Kingdom 53 (11.8)
 Italy 46 (10.3)
 Israel 45 (10.0)
 Denmark 19 (4.2)
 Brazil 16 (3.6)
 Greece 14 (3.1)
 Austria 8 (1.8)
 Sweden 2 (0.4)
Table 2 Characteristics of  icatibant-treated attacks 
in patients with and without LTP
Analysis included attack data for patients who were or were not receiving LTP at 
the time of the attack(s) and who were treated with icatibant for acute attacks
HCP health care provider, LTP long-term prophylaxis
a Some patients reported attacks with LTP as well as without LTP
b P = 0.147 for comparison of very mild/mild/moderate versus severe/very 
severe attacks
c Excludes attacks with missing or unknown data
d Other organs affected by ≥2 attacks include tongue, bladder, esophagus, 
lungs, respiratory tract, breast, genitals, testicles, bowel, stomach, uvula, joints, 
and brain
Characteristic Attacks
With LTP
Attacks
Without LTP
Total
Patients, n 171 323 448a
Attacks, n (%) 973 (30.1) 2255 (69.9) 3228
Attack severity, n (%)b
 nc 813 2029 2842
 Very mild 6 (0.7) 29 (1.4) 35 (1.2)
 Mild 65 (8.0) 161 (7.9) 226 (8.0)
 Moderate 243 (29.9) 759 (37.4) 1002 (35.3)
 Severe 356 (43.8) 803 (39.6) 1159 (40.8)
 Very severe 143 (17.6) 277 (13.7) 420 (14.8)
Attack site, n (%)
 nc 967 2222 3189
 Skin 339 (35.1) 669 (30.1) 1008 (31.6)
 Abdomen 460 (47.6) 1158 (52.1) 1618 (50.7)
 Larynx 29 (3.0) 110 (5.0) 139 (4.4)
 Other  organsd 23 (2.4) 52 (2.3) 75 (2.4)
 Multiple sites 116 (12.0) 233 (10.5) 349 (10.9)
Type of administration, n (%)
 nc 923 2153 3076
 Self-administration 705 (76.4) 1666 (77.4) 2371 (77.1)
 HCP 218 (23.6) 487 (22.6) 705 (22.9)
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Most attacks with LTP were successfully treated with a 
single icatibant injection
Icatibant was self-administered in 76.4% of breakthrough 
attacks and in 77.4% of attacks that occurred without 
LTP. Overall, 803/973 (82.5%) breakthrough attacks and 
1868/2255 (82.8%) attacks without LTP were treated with 
a single dose of icatibant, and without the use of C1-INH 
rescue medication (Fig.  2). Multiple icatibant injections 
were used in 93 (9.6%) breakthrough attacks and in 189 
(8.4%) attacks that occurred without LTP. C1-INH rescue 
medication was used in 95 (9.8%) breakthrough attacks 
and in 221 (9.8%) attacks that occurred without LTP. 
Patients also reported using other medications in addi-
tion to icatibant, the most frequent being androgens, 
analgesics, and antifibrinolytics. These were used in addi-
tion to icatibant in 3.5, 2.4, and 2.8% of breakthrough 
attacks, respectively, and in 1.0, 1.6, and 1.2% of attacks 
without LTP, respectively.
Outcomes of icatibant‑treated HAE attacks were similar 
for attacks with and without LTP
The median times to treatment with icatibant, time to 
resolution, and duration of attack were not significantly 
different for attacks that occurred with versus without 
LTP (Table  4). Among the different types of LTP, only 
the combined treatments (“other”) had a shorter time to 
treatment (P  =  0.029). There was no significant differ-
ence (P  >  0.100) among the different types of LTP with 
respect to time to resolution. Duration of attack was sig-
nificantly longer for breakthrough attacks that occurred 
while using tranexamic acid (P = 0.016), and shorter for 
attacks with C1-INH (P = 0.041). Of note, patients who 
used tranexamic acid for LTP also had longer time to 
treatment and longer time to resolution compared with 
patients who used other types of LTP.
Two patients were previously identified as outliers 
based on their reinjection characteristics [13]. These 
patients used LTP (danazol and C1-INH, respectively) 
during enrollment in the study. The results for icatibant 
reinjection and treatment outcomes between attacks 
that occurred with or without LTP were not significantly 
impacted when data from these outliers were excluded.
Discussion
Prophylactic treatment for C1-INH-HAE has been 
shown to reduce the frequency and severity of attacks [7, 
14, 15]. The present analyses of real-world data from IOS 
support that patients receiving LTP (who usually have 
high disease activity) experience attacks of similar dura-
tion and frequency as patients who do not use LTP. Our 
findings show that icatibant, when used as on-demand 
medication, is similarly effective in controlling attacks in 
patients who are taking LTP and in those who are not.
In our dataset, patients across all LTP groups expe-
rienced breakthrough attacks, including those that 
involved the larynx and those that significantly impaired 
physical function. Breakthrough attacks may have 
occurred because local C1-INH levels fell below or did 
not reach the normal range despite administration of 
LTP, resulting in inadequate regulation of the contact 
system [1]. It is possible that doses of LTP administered 
were insufficient, or the dosing was not frequent enough 
Table 3 Duration of treatment and attack frequency for each type of LTP
C1-INH C1-inhibitor, IQR interquartile range, LTP long-term prophylaxis
a The start date of LTP was imputed to the date of the first treated attack if the patient started LTP before the date of the first attack
b The sum of maximum treatment duration. Treatments received by patients were included even if they were not related to treated attacks
c Icatibant-treated attacks that occurred with or without LTP
d Androgens include danazol, stanozolol, and oxandrolone
e The duration (follow-up time) of icatibant treatment for patients who never received LTP. Duration was computed from first attack date to extract date, death date, 
or discontinuation date, as applicable. Patients who reported attacks with and without LTP were excluded
Type of LTP No. of attacks (%) No. of patients (%) Duration of LTP,  ya Attack frequency 
(attacks/year)c
Mean (SD) Median (IQR) Total  durationb
C1-INH 121 (12.4) 15 (8.8) 3.4 (1.4) 3.1 (2.6–3.7) 51.5 2.3
C1-INH/androgensd 9 (0.9) 4 (2.3) 4.6 (1.4) 4.6 (3.4–5.8) 18.6 0.5
C1-INH/androgens/
tranexamic acid
4 (0.4) 2 (1.2) 3.3 (1.9) 3.3 (1.9–4.6) 6.5 0.6
C1-INH/tranexamic acid 24 (2.5) 2 (1.2) 3.8 (1.1) 3.8 (3.1–4.6) 7.7 3.1
Androgens 542 (55.7) 108 (63.2) 3.5 (1.9) 3.4 (2.2–5.0) 372.7 1.5
Androgens/tranexamic acid 41 (4.2) 9 (5.3) 5.0 (1.3) 4.5 (4.1–6.0) 44.8 0.9
Tranexamic acid 232 (23.8) 43 (25.1) 3.4 (1.8) 3.8 (1.6–4.6) 147.1 1.6
Overall 973 171 3.5 (1.8) 3.6 (2.2–4.8) 620.5 1.6
No  LTPe 1941 277 3.6 (1.8) 3.4 (2.1–5.0) 985.4 2.0
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(n = 466)
Tranexamic acid
(n = 165)
C1-INH
(n = 110)
Other†
(n = 72)
No LTP
(n = 2029)
0
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Type of LTP
a
b
Very mild/mild/moderate Severe/very severe
68.9% 53.3% 45.5% 55.6% 53.2%
31.1%
46.7%
54.5%
44.4% 46.8%
P = 0.043 P = 0.989  P = 0.193  P = 0.850
Androgens*
(n = 538)
Tranexamic acid
(n = 230)
C1-INH
(n = 121)
Other†
(n = 78)
No LTP
(n = 2222)
0
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Type of LTP
A
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s,
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A
tta
ck
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Skin Abdomen
13.9% 7.8% 14.9% 6.4% 10.5%
36.1%
42.2%
51.7%
45.5%
44.9% 5.0%
8.9%
Larynx Other organs Multiple sites
46.7%
1.1%
2.2%
33.5%
3.9%
2.9%
29.8%
41.0%
30.1%
4.1%
5.8%
6.4%
52.1%
2.3%
1.3%
Fig. 1 a Severity and b site of attacks by type of long-term prophylaxis (LTP). P values compared severity of attacks with LTP versus attacks without 
LTP. Attacks with a unknown severity and b unknown attack site were excluded. *Androgens include danazol, stanozolol, and oxandrolone. †Other 
includes all LTP treatments that combined >1 type of LTP
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to completely prevent attacks. In addition, data regard-
ing patient adherence to LTP were not available, and 
breakthrough attacks may have resulted from delays in 
dosing, or errors in the administration of prophylactic 
medications.
Patients who are candidates for LTP typically have 
more severe disease (i.e., frequent and severe attacks) 
[1, 3, 4]. Approximately half of the attacks reported in 
patients taking LTP were severe/very severe, which is 
comparable to attacks that occurred without LTP. This 
A
tta
ck
s,
 %
1 injection 2 injections  ≥ 3 injections 1 injection 2 injections  ≥ 3 injections
0
20
40
60
80
100 12.5%
82.5%
0.5% 6.8%7.4%
7.9%
1.6%
82.8%
8.8%
1.0% 0.5%
With LTP
(n = 973)
Without LTP
(n = 2255)
90.4%
9.0%
91.6%
7.8%
No C1-INH rescue medication C1-INH rescue medication
Fig. 2 Proportion of attacks treated with 1, 2, or ≥3 injections of icatibant and C1-inhibitor (C1-INH) rescue medication(s) in patients who received 
or did not receive long-term prophylaxis (LTP)
Table 4 Time to treatment, time to resolution, and duration of attack for icatibant-treated breakthrough attacks by type 
of LTP
C1-INH C1-inhibitor, IQR interquartile range, LTP long-term prophylaxis
a Androgens include danazol, stanozolol, and oxandrolone
b Other includes all LTP treatments that combined >1 type of LTP
c Only attacks with complete data for all outcomes were included in this analysis
d P value derived from a mixed model of repeated measures and compares attacks with versus without LTP
Type of LTP
LTP Androgensa Tranexamic acid C1‑INH Otherb No LTP
No. patients 93 56 24 5 9 179
No.  attacksc 391 226 92 36 37 781
Time to treatment
 Median (IQR), h 1.5 (0.5–4.0) 1.3 (0.5–4.0) 2.0 (0.5–5.9) 1.5 (0.1–2.1) 0.8 (0.5–2.0) 1.0 (0.3–4.0)
 P  valued 0.090 0.095 0.745 0.681 0.029
Time to resolution
 Median (IQR), h 4.5 (2.0–12.0) 5.0 (2.0–11.5) 7.0 (2.0–20.5) 3.0 (2.4–4.0) 4.0 (2.0–24.5) 6.0 (2.0–14.6)
 P value 0.869 0.642 0.317 0.103 0.565
Duration of attack
 Median (IQR), h 8.0 (4.0–17.0) 8.0 (3.5–17.0) 11.6 (6.0–25.3) 4.0 (3.1–5.8) 7.0 (3.0–25.0) 9.0 (3.8–20.0)
 P value 0.543 0.984 0.016 0.041 0.741
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further emphasizes the fact that breakthrough attacks 
can occur often and can be severe. Interestingly, there 
was a higher proportion of severe/very severe attacks 
in patients who were using androgens for LTP (68.9%) 
compared with patients who were using tranexamic 
acid, C1-INH, or a combination of the three treatments 
(45.5–55.6%). However, we cannot make conclusions 
regarding efficacy from this observation as the severity 
of disease prior to starting LTP among the patients who 
used the various types of LTP is not known. Furthermore, 
androgens are associated with numerous side effects [16], 
which may compromise patient compliance and subse-
quently treatment effectiveness.
Irrespective of LTP use, patients responded well to icat-
ibant, and >80% of C1-INH-HAE attacks were success-
fully treated with only a single injection of icatibant. This 
is consistent with previous results reported from IOS [13, 
17]. The rate of on-demand medication use was compa-
rable for attacks that occurred with or without LTP, and 
there was no difference in treatment outcomes between 
attacks that occurred with or without LTP. Duration of 
attack was longer for attacks that occurred while taking 
tranexamic acid, and shorter with C1-INH treatment, in 
accordance with previous reports [14, 18]. Statistically 
significant effects of individual types of LTP on time to 
treatment and duration of attack should be interpreted 
with caution in this analysis, however, as both the num-
ber of patients and frequency of attacks within these 
groups were small.
Overall, the findings from IOS indicate that attack 
characteristics and outcomes with icatibant treatment 
were similar for patients with high disease activity (i.e., 
those who require LTP treatment), and for those with 
less severe disease. These results are consistent with our 
clinical experience with icatibant treatment in patients 
with C1-INH-HAE. Furthermore, the results support the 
theory that attacks in patients with high- and low-disease 
severity share a common pathogenic mechanism [19]. 
Specifically, this involves elevation of bradykinin levels 
subsequent to contact system activation in the absence 
of sufficient, protective C1-INH levels; icatibant counter-
acts this activity by inhibiting the bradykinin receptor.
The results also revealed some surprising information 
concerning the use of icatibant plus add-on medications 
to treat attacks. Although attenuated androgens and 
antifibrinolytics are not recommended for the treatment 
of acute attacks [4], approximately 3% of total attacks 
were treated with these medications following dosing 
with icatibant. Of the 56 attacks that were treated with 
icatibant plus on-demand androgens, 34 (60.7%) attacks 
occurred while androgens were also used for LTP, sug-
gesting that if icatibant were determined to be insuffi-
cient for resolving an attack, patients simply resorted to 
readily available treatments for rescue. The remaining 
22 attacks that were treated with on-demand androgens 
occurred without LTP; these attacks were reported by 11 
patients, and may reflect a lack of knowledge on the part 
of the patients or physicians regarding selection of appro-
priate treatments for acute attacks. Androgens might also 
be used as a form of short-term prophylaxis to reduce the 
chance of occurrence of a later attack (for example prior 
to traveling or a dental procedure).
Some limitations of this study should be noted. 
Although the data suggest that the attack rate while using 
C1-INH, androgens, or tranexamic acid for LTP was sim-
ilar and that LTP was effective in reducing the attack rate 
of patients with severe disease to the same rate as patients 
with less severe disease, this was not a randomized trial 
in which patients were randomly assigned to receive LTP, 
and adherence to LTP treatment was not monitored. The 
goal of this analysis was to evaluate the effectiveness of 
icatibant in treating breakthrough attacks, rather than to 
compare different LTP options. Data confirming disease 
severity prior to initiation of prophylactic treatment were 
also not available as a baseline comparison. In addition, 
the C1-INH treatment group was relatively small. Thus, 
these data cannot be used to evaluate the effectiveness of 
LTP or to compare the various LTP treatments. The small 
number of C1-INH users in the database population does 
reflect our clinical experience in that very few patients 
use C1-INH at the recommended dose of 1000 U every 
3–4 days; instead, doses and regimens are often adjusted 
according to individual patients’ responses. Thus it is dif-
ficult to fully assess the impact of C1-INH in comparison 
to other LTP treatments. In addition, C1-INH is indi-
cated for both LTP and the treatment of acute attacks, 
and patients who use C1-INH for LTP often use it to treat 
breakthrough attacks as well [20]. As this analysis only 
includes attacks treated with icatibant, it is possible that 
some attacks were treated with C1-INH or other medica-
tions instead of icatibant, thus the true number of attacks 
with and without LTP could potentially be higher than 
reported here. Information on attacks that were treated 
with medications other than icatibant is not included in 
IOS. Of the 121 breakthrough attacks that occurred while 
on prophylaxis with C1-INH, 20 attacks were treated 
with rescue medication, and C1-INH was used exclu-
sively for all 20 attacks. This further emphasizes the high 
frequency of C1-INH use for both prophylaxis and acute 
treatment indications.
Conclusions
Icatibant was successfully used to treat both break-
through attacks in patients with C1-INH-HAE receiving 
prophylaxis as well as attacks that occurred without LTP. 
Patients who are prescribed LTP should be aware of the 
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potential for breakthrough attacks, including those of 
high severity and involving the larynx, and should be pre-
pared by having easily accessible emergency treatment.
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